Background: Concomitant chemo-radiotherapy is the reference treatment for non-resectable locally-advanced Non-Small Cell Lung Cancer (NSCLC). Increasing radiotherapy total dose in the whole tumour volume has been shown to be deleterious. Functional imaging with positron emission tomography (PET/CT) offers the potential to identify smaller and biologically meaningful target volumes that could be irradiated with larger doses without compromising Organs At Risk (OAR) tolerance. This study investigated four scenarios, based on FDG and F-miso PET/CT, to delineate the target volumes and derive radiotherapy plans delivering up to 74Gy.
Method: Twenty-one NSCLC patients, selected from a prospective phase II trial, had FDG- and F-miso PET/CT before the start of radiotherapy and FDG PET/CT during the radiotherapy (42Gy). The plans were based planned on a standard plan delivering 66 Gy (plan 1) and on three different boost strategies to deliver 74Gy total dose in pre-treatment FDG hotspot (70% of SUV) (plan 2), pre-treatment F-miso target (SUV > 1.4) (plan 3) and per-treatment FDG residual (40% of SUV). (plan 4).
Results: The mean target volumes were 4.8 cc (± 1.1) for FDG hotspot, 38.9 cc (± 14.5) for F-miso and 36.0 cc (± 10.1) for per-treatment FDG. In standard plan (66 Gy), the mean dose covering 95% of the PTV (D95%) were 66.5 (± 0.33), 66.1 (± 0.32) and 66.1 (± 0.32) Gy for FDG hotspot, F-miso and per-treatment FDG. In scenario 2, the mean D95% was 72.5 (± 0.25) Gy in FDG hotspot versus 67.9 (± 0.49) and 67.9 Gy (± 0.52) in F-miso and per-treatment FDG, respectively. In scenario 3, the mean D95% was 72.2 (± 0.27) Gy to F-miso versus 70.4 (± 0.74) and 69.5Gy (± 0.74) for FDG hotspot and per-treatment FDG, respectively. In scenario 4, the mean D95% was 73.1 (± 0.3) Gy to FDG per-treatment versus 71.9 (± 0.61) and 69.8 (± 0.61) Gy for FDG hotspot and F-miso, respectively. The dose/volume constraints to OARs were matched in all scenarios.
Conclusion: Escalated doses can be selectively planned in NSCLC target volumes delineated on FDG and F-miso PET/CT functional images. The most relevant strategy should be investigated in clinical trials.
Trial Registration: (RTEP5, NCT01576796 , registered 15 june 2012).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199734 | PMC |
| http://dx.doi.org/10.1186/s13014-018-1147-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A bibliometric analysis based on hotspots and frontier trends of positron emission tomography/computed tomography utility in bone and soft tissue sarcoma.
Front Oncol
June 2024
Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Purpose: This study aimed to analyze articles on the diagnosis and treatment of bone and soft tissue sarcoma using positron emission tomography (PET)/computed tomography (CT) published in the last 13 years. The objective was to conduct a bibliometric analysis and identify the research hotspots and emerging trends.
Methods: Web of Science was used to search for articles on PET/CT diagnosis and treatment of bone and soft tissue sarcoma published from January 2010 to June 2023.
Trends and Hotspots in Global Radiomics Research: A Bibliometric Analysis.
Technol Cancer Res Treat
March 2024
Department of Ultrasound, The First Hospital of China Medical University, Shenyang, P. R. China.
The purpose of this research is to summarize the structure of radiomics-based knowledge and to explore potential trends and priorities by using bibliometric analysis. Select radiomics-related publications from 2012 to October 2022 from the Science Core Collection Web site. Use VOSviewer (version 1.
View Article and Find Full Text PDFA Comparative Study of Lymphatic Filariasis-Related Perceptions among Treated and Non-Treated Individuals in the Ahanta West Municipality of Ghana.
Trop Med Infect Dis
September 2022
Parasitology Department, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana.
Ghana joined the Global Programme to Eliminate Lymphatic Filariasis (GPELF), established in the year 2000, with the aim of eliminating the disease as a public health problem through annual mass treatment of entire endemic populations. Since 2001, the country has implemented mass drug administration (MDA) in endemic districts, with great reductions in the population at risk for infection. However, in many districts, the elimination programme is faced with the presence of hotspots, which may be due in part to individuals not taking part in MDA (either intentionally or unintentionally) who may serve as reservoirs to sustain transmission.
View Article and Find Full Text PDFPembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Lancet Oncol
November 2022
Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Article Synopsis
- Patients with stage IIB or IIC melanoma had a higher chance of their cancer coming back after surgery, but using a drug called pembrolizumab helped them stay cancer-free longer than a placebo.
- The KEYNOTE-716 trial tested this drug on patients in many hospitals around the world, focusing on those aged 12 and older with specific types of melanoma.
- After several treatments with pembrolizumab or placebo, researchers looked at how well the drug worked and how safe it was for the patients involved.
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Eur J Cancer
November 2022
UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Background: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life (HRQoL) results are reported.
Methods: Patients were randomly assigned 1:1 to pembrolizumab 200 mg (2 mg/kg, patients ≥12 to <18 years) Q3W or placebo for ≤17 cycles or until disease recurrence, unacceptable toxicity, or withdrawal.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!